NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · ESPR · USD
Stock price, earnings
Quote as of Jul 13, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Esperion Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.83% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Esperion Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $69.11M+33.68% vs estimate |
| Q3 2024 | Nov 7, 2024 | -$0.15-7.14% vs estimate | $51.63M-16.12% vs estimate |
|---|
| Q2 2024 | Aug 12, 2024 | -$0.33-120.0% vs estimate | $73.83M+55.46% vs estimate |
|---|
THE ANALYST VIEW
25 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$64.46+$1.44 (+2.28%)
PTC Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.06% below the high.
$37.23-$0.89 (-2.33%)
Agios Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.07% below the high.
$24.03+$0.80 (+3.44%)
Collegium Pharmaceutical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.69% below the high.
$7.22+$0.13 (+1.83%)
Emergent BioSolutions Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.65% below the high.
$0.29-$0.01 (-4.69%)
Heron Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.37% below the high.
$0.88+$0.05 (+5.73%)
Karyopharm Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.99% below the high.
